Skip to main content

Advertisement

Table 2 Multivariate analyses of outcomes

From: Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients

Outcome Hazard ratio (95% CI) P value
ANC recovery
 Cohort ATG-PTCy vs ATG 0.29 (0.21–0.41) < 0.001
Other significant factors
 Mononuclear cell count 1.09 (1.04–1.14) < 0.001
 CD34+ cell count 1.08 (1.01–1.15) 0.012
Platelet recovery
 Cohort ATG-PTCy vs ATG 0.30 (0.21–0.42) < 0.001
Other significant factors
 Mononuclear cell count 1.06 (1.01–1.11) 0.008
Acute GvHD ≥ grade 2
 Cohort ATG-PTCy vs ATG 0.58 (0.35–0.96) 0.036
Acute GvHD ≥ grade 3
 Cohort ATG-PTCy vs ATG 0.28 (0.11–0.69) 0.006
Total chronic GvHD
 Cohort ATG-PTCy vs ATG 0.60 (0.38–0.99) 0.047
Non-relapse mortality
 Cohort ATG-PTCy vs ATG 0.26 (0.08–0.75) 0.014
Disease risk index
 Low/int vs high 0.28 (0.12–0.68) 0.005
Relapse
 Cohort ATG-PTCy vs ATG 0.65 (0.28–1.50) 0.31
Disease-free survival
 Cohort ATG-PTCy vs ATG 0.44 (0.22–0.86) 0.016
Disease risk index
 Low/int vs high 0.51 (0.27–0.99) 0.048
Overall survival
 Cohort ATG-PTCy vs ATG 0.47 (0.22–1.01) 0.055
Disease risk index
 Low/int vs high 0.48 (0.23–0.99) 0.048
GVHD and relapse-free survival
 Cohort ATG-PTCy vs ATG 0.59 (0.38–0.92) 0.021